Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.41% is 78% below its 5-year average of 6.41%, near the low end of its 5-year range (0.00%–375.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.60% above its 12-month average of 1.16%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.41%.
DEBT TO ASSETS RATIO
1.41%
DEBT TO ASSETS RATIO AVG TTM
1.16%
DEBT TO ASSETS RATIO AVG 3Y
4.15%
DEBT TO ASSETS RATIO AVG 5Y
6.41%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+21.60%
CURRENT VS 3Y AVG
-66.09%
CURRENT VS 5Y AVG
-78.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1462.76%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$58.06M
Debt to Assets Ratio
1.41%
TTM Avg
1.16%
3Y Avg
4.15%
5Y Avg
6.41%
Market Cap
$58.29M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.76M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.44M
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.01M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.18M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.02M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | 1.41% | 1.16% | 4.15% | 6.41% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | 0.00% | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | 0.00% | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | 0.09% | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | 0.50% | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | 0.00% | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | 0.01% | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | 0.04% | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | 0.06% | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | 0.00% | N/A | N/A | N/A |
Debt/Assets
1.4%
Debt/Equity
0.02
Current Ratio
10.98
Interest Coverage
-32.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.41% |
| 2026-03-31 | 1.28% |
| 2025-12-31 | 1.19% |
| 2025-09-30 | 1.90% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 375.99% |
| 2024-06-30 | 6.87% |
| 2024-03-31 | 12.72% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 13.24% |
| 2023-06-30 | 11.14% |
| 2023-03-31 | 13.86% |
| 2022-12-31 | 12.77% |
| 2022-09-30 | 7.38% |
| 2022-06-30 | 11.25% |
| 2022-03-31 | 10.01% |
| 2021-12-31 | 10.49% |
| 2021-09-30 | 9.90% |
| 2021-06-30 | 2.80% |
| 2021-03-31 | 2.90% |
| 2020-12-31 | 2.34% |
| 2020-09-30 | 2.41% |
| 2020-06-30 | 8.69% |
| 2020-03-31 | 8.55% |
| 2019-12-31 | 8.43% |
